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Abstract
It is known that iron overload may lead to an increased risk for many diseases. According to GWAS studies, iron regulatory protein
HFE gene variant H63D (rs1799945) was associated with hypertension, an observation which we were able to conﬁrm also in our
TAMRISK cohort. Thus, it is possible that abnormalities in iron homeostasis may predispose to hypertension. This prompted us to
study whether there is an association between hypertension and another iron overload-associated gene, hemojuvelin (HJV), which
has 2 common polymorphic sites (rs 16827043, rs7536827).
The study included 336 hypertensive cases and 480 controls. All participants were 50- year-old Finnish men and women, and the
data was collected from the Tampere adult population cardiovascular risk study (TAMRISK). Genotypes were determined using
Competitive Allelic Speciﬁc PCR (KASP).
We found that the minor variant of the HJV polymorphic site rs16827043 (G-allele) is a statistically signiﬁcant factor associated with
hypertension among 50 year-old individuals compared with the AA genotype carriers (OR=1.66, 95%CI: 1.06 – 2.60, P=0.03). The
risk was even higher when overweight subjects (BMI>30) were excluded from the analyses. For the other polymorphic variant
rs7536827, association with hypertension was found only among normal or slightly overweight A-allele carriers.
In conclusion, HJV genetic variants were associated with essential hypertension in Finnish subjects from the TAMRISK cohort.
Previous studies together with the present one indicate that individuals with possible dysregulation of iron metabolism may have
higher risk for hypertension than those with normal iron homeostasis.
Abbreviations: BMI = body mass index, CI = conﬁdence interval, HFE = histocompatibility complex class I-like transmembrane
protein (hemochromatosis protein), HJV = hemojuvelin (previously HFE2), PCR = polymerase chain reaction, PHE = periodic health
examination.
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Iron metabolism has been studied extensively to understand how
the body maintains iron homeostasis. It is now known that
hepcidin plays an important role on intestinal iron absorption
and iron recycling in macrophages. Hepcidin functions by
decreasing the amount of iron released from macrophages orEditor: Ming Zhang.
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1absorbed from intestine. It is also known that hepcidin deﬁency
may lead to severe iron overload inmultiple organs.[1–4] Hepcidin
synthesis is complexly regulated by different proteins and
pathways.[5] Two important transmembrane proteins, HFE
(histocompatibility complex class I-like transmembrane protein)
and HJV (hemojuvelin), are key modulators of hepcidin
expression. HJV acts as a bone-morphogenetic protein (BMP)
co-repressor, driving hepcidin transcription via the BMP-SMAD
signaling cascade.[6] Using a mouse model, Kent et al[7] showed
that HFE and HJV operate in the same pathway for regulation of
hepcidin expression and iron metabolism. Recently, Wu et al[8]
showed that HJV is the key regulator of hepcidin and that HFE
acts in an HJV-dependent manner. Some mutations in these 2
proteins have been associated with severe iron overload in
patients with hereditary haemochromatosis.[9,10]
Dysregulation in iron homeostasis may also lead to mild iron
overload, which has not been generally taken into account. Two
previous GWAS studies[11,12] have found an association between
HFE (H63D) genetic variant and hypertension. We were able to
replicate this association in the TAMRISK cohort and showed
that carriers of the mutation had higher risk for hypertension
than those without this mutation.[13]
Mutations in the HJV gene that lead to severe iron overload are
rare, although over 40 mutations of HJV have been recog-
nized.[14] Therefore, we analyzed 2 relatively frequent variants of
this gene that have been shown to mediate dysfunctional iron
[15]
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possible association between these HJV genetic variants and
hypertension in the Finnish TAMRISK cohort.2. Materials and methods
2.1. Study population
The Tampere adult population cardiovascular risk study (TAM-
RISK) is a prospective, longitudinal population-based health survey
study in Tampere, a city in southern Finland with a population of
210 000. The data for the TAMRISK study was collected from the
periodic health examinations (PHE) done for 50-year-old men and
women living inTampere. The PHE includedone60-minute session
with a public health nurse at the center’s health examination unit as
previously described.[13,16] TAMRISK data includes information of
risk factors for hypertension: blood pressure, weight, family history
of cardiovascular diseases, lipid values and smoking, diabetes, and
exercise habits. Physical activity was deﬁned as times of exercise/
week (enhanced breathing and sweating). Current and previous
diseases were identiﬁed based on self-report of diagnosis by a
physician, including hypertension. Cases in this study were the
subjectswhohadhypertension and/orCADat the age of 50 years as
diagnosed by a physician by normal healthcare procedures. For
most patients, physicians diagnose hypertension when blood
pressure readings are consistently 140/90mm Hg or above. For
each case, at least 1 normotensive control with the same sex and
similar smoking habits were chosen from a PHE cohort (n=6000).
Smoking status was evaluated based on self-reporting.
Using the patient’s national identity code, data on hospital-
izations including ICD-10 codes for discharge diagnoses were
obtained from the Finnish National Hospital Discharge Registry
(HILMO) maintained by the National Institute of Health and
Welfare. Prevalence of ischemic heart diseases (I20-I25) were
followed up from 2005 to 2014 until the subjects were on the
average 60 years old.
Buccal swabs for DNA extraction and a permissions form to
use PHE data were collected by mail separately of the physical
examination. The DNA samples were collected during years
2006–2010. Informed consent was obtained from all partic-Table 1
Clinical characteristics of cases and controls of the study population
Study population
Cases (n=336) Controls (n=480)
Age, y 50±0 50±0
BMI, kg/m2 28.8±5.1 25.5±3.7
Hemoglobin 147.0±13.4 145.4±13.2
Cholesterol, mmol/L 5.38±0.99 5.37±0.88
LDL cholesterol, mmol/L 3.16±0.88 3.17±0.82
Glucose, mmol/L 5.17±1.29 4.86±0.53
Systolic blood pressure, mm Hg 142.7±16.6 129.3±14.8
Diastolic blood pressure, mm Hg 92.8±8.8 84.4±9.1
Hypertension % 100 0
Diabetes % 12.8 0
Myocardial infarction % 3.6 0
Exercise, at least twice a week, % 62.8 57.2
Family history of hypertension % 71.6 42.5
Gender, male, % 58.4 56.8
Data is presented as mean±SD
BMI = body mass index, LDL= low density lipoprotein, SD= standard deviation.
2ipants. The Ethics Committees of the Tampere University
Hospital and the City of Tampere approved the study.2.2. Genotyping
DNA was extracted from buccal swabs using a commercial
kit (Qiagen Inc., Valencia, CA). Genotyping was performed
using KASP (Competitive Allelic Speciﬁc Ampliﬁcation) genotyp-
ing services at KBioscience Institute, UK. Details of this method
can be obtained from https://www.lgcgroup.com/genotyping/.
2.3. Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics 23,
andHardy–Weinberg equilibrium of the genotypes was calculated
using OEGE (online encyclopedia calculator for genetic epidemi-
ology studies).[17] T-test and 1-way ANOVA for continuous
variables (clinical characteristics) and chi-square test for categori-
cal variables (hypertension, coronary artery disease) were applied
for the comparison of HJV genotype groups. Associations of the
genotyped HJV gene variants with hypertension/coronary artery
disease with risk factors (BMI, glucose, cholesterol and gender)
were analyzed using logistic regression analysis. P-values less than
0.05 were considered signiﬁcant.
3. Results
Clinical characteristics of the study population at the age of 50
years are presented in Table 1. Brieﬂy, the case group comprised
336 hypertensive cases and control group 480 normotensive
subjects with the same sex distribution and similar smoking
habits. A total of 78 subjects were found to have coronary artery
disease when followed up to 60 years of age.
Genotyping was successful in 808 subjects for the HJV
rs16827043 (A>G) and in 795 subjects for the rs7536827 (A>
T). The measured genotype frequencies were not signiﬁcantly
different from the expectations of Hardy–Weinberg equilibrium
(x2=0.22 for rs16827043 and x2=0.09 for rs7536827). The
clinical characteristics according to different genotypes are
shown in Tables 2 and 3.and subpopulation with BMI < 30.
Subpopulation with BMI<30
P (Cases n=239) Controls (n=399) P
50±0 50±0
<0.001 25.9±2.8 24.8±2.7 <0.001
0.165 146.3±13.0 144.8±13.1 0.240
0.887 5.42±1.02 5.37±0.88 0.510
0.838 3.15±0.92 3.16±0.83 0.921
<0.001 5.11±1.45 4.85±0.53 0.001
<0.000 142.7±17.0 128.4±14.3 <0.000
<0.000 92.7±8.9 83.8±8.7 <0.000
100 0
<0.000 9.6 0 <0.000
<0.000 3.2 0 0.001
0.135 62.8 55.5 0.102
<0.000 74.7 41.5 <0.000
0.319 58.3 64.1 0.165
Table 2
Clinical characteristics of the study population stratiﬁed according to HJV rs 16827043 genotypes.
HJV P P
rs16827043 AA AG GG AA vs AG vs GG AA vs (AG+GG)
n at 50 697 108 3
Hypertension % 41.3 51.0 100 0.024 0.041
Coronary artery disease, %, n=78 9.9 8.3 0 0.745 0.729
Systolic blood pressure, mm Hg 134. 7±16.8 137.7±16.7 136.7±13.3 0.237 0.095
Diastolic blood pressure, mm Hg 87.7±9.8 89.6±9.7 98.9±7.2 0.035 0.033
Body mass index, kg/m2 26.9±4.7 27.1±4.2 25.5±2.3 0.784 0.746
Cholesterol, mmol/L 5.35±0.99 5.55±0.90 5.53±0.97 0.151 0.052
Glucose, mmol/L 5.03±1.20 5.02±0.68 4.83±0.25 0.953 0.898
HJV = hemojuvelin (previously HFE2).
P values from the chi-square test for categorical variables and 1 way ANOVA or T-test for continuous variables.
P values < 0.05 are in bold.
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individuals who were homozygous for the GG genotype and they
were combined to the GA genotype group. At the age of 50 years,
58 of 111 G-allele carriers (52,2%) had diagnosed hypertension
compared to 287 of 697 (41.3%) of those homozygous for the
wild type (AA), respectively (P=0.041). Also, diastolic blood
pressure readings were signiﬁcantly higher among G-allele
carriers (Table 2). When the risk for hypertension was analyzed
by logistic regression using HJV variants, BMI, glucose,
cholesterol, and gender as explainable variables, OR for HJV
G-allele carriers was 1.66 (P=0.03, 95%CI: 1.06–2.60), for BMI
1.19 (P<0.001, 95% CI: 1.15–1.24), for glucose 1.49 (P<
0.001, 95% CI: 1.16–1.92), for cholesterol 0.99 (P=0.96, 95%
CI: 0.84–1.18), and for gender 1.50 (P=0.02, 95% CI:
1.07–2.09) compared with AA genotype. In order to exclude
the strong effect of BMI on hypertension, we also analyzed a
subpopulation of the study participants with normal or only
slightly elevated BMI. When overweight participants (BMI>30)
were excluded from the analyses, the risk for hypertension among
G-allele carriers remained signiﬁcant (OR=1.80, 95% CI
1.09–2.98, P=0.02). Adjusted and unadjusted results are in
Table 4. No statistically signiﬁcant association with coronary
artery disease was found (Table 2).
For the other polymorphic site (rs7536927, T>A), no
association between genotypes or combined alleles and hyper-
tension was found in the whole study population (P=0.29 for
genotypes and P=0.24 for A-allele carriers). However,
when subjects were stratiﬁed according to weight, carriers of
the A-allele whose BMI was less than 30 had more often
hypertension compared with those homozygous for the wild typeTable 3
Clinical characteristics of the study population stratiﬁed according t
HJV
rs7536827 AA AT
n at 50 186 397 2
Hypertension % 39.2 45.5
Coronary artery disease, %, n=78 8.1 10.4
Systolic blood pressure, mm Hg 134.9±16.3 135.5±16.6 134
Diastolic blood pressure, mm Hg 87.6±10.2 88.5±9.7 87
BMI, kg/m2 26.6±4.8 27.1±4.6 26
Cholesterol, mmol/L 5.37±0.95 5.34±1.05 5.
Glucose, mmol/L 5.03±0.91 5.01±1.19 5.
BMI = body mass index.
P values from the chi-square test for categorical variables and 1-way ANOVA or T-test for continuous
P values < 0.05 are in bold.
3(TT) (OR=1.56, P=0.04, 95%CI 1.01–2.39) (Table 4.) As with
the rs7536827, no association with coronary artery disease was
found (Table 2).4. Discussion
The results of the present study suggest that genetic variation in
theHJV gene is signiﬁcantly associated with hypertension in a 50-
year-old Finnish population. Previous studies of the HJV and
HFE genetic polymorphisms have concentrated mainly on
hemochromatosis. Our results and those of others indicate that
disturbances in iron metabolism may also increase the risk for
hypertension.[18,19] We found no impact of the 2 studied HJV
polymorphisms on coronary artery disease.
In this paper, we show that the minor allele G of the
HJV variant rs16827043 was associated with hypertension.
In addition, the association between the minor allele and
hypertension was even stronger among normal- or only
slightly overweight subjects. For the other HJV polymorphic
site rs7536827, no statistically signiﬁcant association
with hypertension was found. However, when T allele carriers
were combined and obese subjects were excluded, also this
genetic variation associated with hypertension. Although the
mechanism is not known, our result together with previous ones
provides a further link between iron metabolism and
hypertension.[11–13,20]
Mild iron overload is one possible explanation for higher
blood pressure of carriers of the HJV minor variants, as has been
suggested for H63D.[13] Both of these membrane receptors are
involved in pathways leading to hepcidin transcription. A recento HJV rs 7536827 genotypes.
P P P
TT AA vs AT vs TT AA vs (AT+TT) TT vs (AA+AT)
12
40.9 0.293 0.602 0.241
9.4 0.680 0.161 1.000
.4±17.7 0.738 0.898 0.475
.4±9.6 0.362 0.529 0.302
.9±4.5 0.406 0.250 0.767
46±0.89 0.340 0.846 0.151
07±1.24 0.841 0.949 0.567
variables.
[5] Silva B, Faustino P. An overview of molecular basis of iron metabolism
Table 4
Unadjusted and adjusted OR results obtained from logistic regression analysis for hypertension.
Univariate model
∗
Multivariate model†
OR (95% CI) P OR (95% CI) P
All participants
rs16827043, G-allele vs AA 1.54 (1.02–2.32) 0.041 1.66 (1.06–2.60) 0.028
rs7536827, A-allele vs TT 1.26 (0.88–1.69) 0.247 1.36 (0.94–1.98) 0.103
BMI<30 kg/m2 OR (95% CI) P OR (95% CI) P
rs16827043, G-allele vs AA 1.70 (1.05–2.75) 0.032 1.80 (1.09–2.98) 0.022
rs7536827, A-allele vs TT 1.48 (0.99–2.22) 0.056 1.56 (1.01–2.39) 0.044
BMI=body mass index, CI= conﬁdence interval, OR= odds ratio.
∗
Univariate model with HJV SNP alone
†Multivariate2 model with HJV SNP, BMI, glucose, cholesterol, and gender as explainable variables
Nikkari et al. Medicine (2017) 96:5 Medicinestudy has reported that HJV functions as enhancer for iron
signaling to hepcidin. Since hepcidin is the main iron regulatory
hormone, disturbances in pathways affecting hepcidin expression
may block its function as a feedback inhibitor of iron absorption.
However, only complete loss of hepcidin in humans is responsible
for rare yet severe forms of massive body iron overload.[21]
In Finland, tests for assessing body iron levels (serum ferritin
and transferrin saturation) are not routinely measured and
therefore a limitation of the TAMRISK study population is the
lack of these saturation markers. However, it has previously been
published that men with essential hypertension had greater iron
stores than normotensive controls.[20]
It is known that prevalence of hypertension is higher in obese
than in lean populations and there is nearly linear relationship
between BMI and blood pressure.[22] It has previously been shown
that there is a gene-environmental association between hyperten-
sion genes and BMI. Thus, obesity will override the genetic
effect.[13,23] The association of HJV and hypertension was similar
or even stronger fornormalweight andslightlyoverweight subjects
than in obese subjects, conﬁrming the role of HJV.
Although the mechanism is not yet known, our results suggest
that the minor allele G of the HJV variant (rs16827043) is
associated with higher risk for hypertension at the age of 50
years, compared with the AA-genotype carriers. In addition, we
found that among normal or slightly overweight individuals, also
T-allele of theHJV rs7536827 increases the risk for hypertension.
It is therefore possible that dysregulation in iron metabolism is a
signiﬁcant factor behind hypertension. Abnormalities in iron
homeostasis and relationship between iron metabolism and
hypertension warrant further studies.
Acknowledgments
The authors thank all of the participants of the TAMRISK study
andMirka Pietiläinen and Ulla Saarijoki for their skilful technical
assistance.
References
[1] Crownover B, Covey C. Hereditary hemochromatosis. Am Fam
Physician 2013;87:183–90.
[2] Means RTJr. Hepcidin and iron regulation in health and disease. Am J
Med Sci 2013;345:57–60.
[3] Loreal O, Haziza-Pigeon C, Troadec M, et al. Hepcidin in iron
metabolism. Curr Protein Peptide Sci 2005;6:279–91.
[4] Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron
regulatory peptide hepcidin is regulated by anemia, hypoxia and
inﬂammation. J Clin Invest 2002;110:1037–44.4regulation and the associated pathologies. Biochimica et Biophysica Acta
2015;1852:1347–59.
[6] Babitt JL, Huang FW,Wrighting DM, et al. Bone morphpgenetic protein
signaling by hemojuvelin regulates hepcidin expression. Nat Genet
2006;38:531–9.
[7] Kent P, Wilkinson N, Constante M, et al. Hfe and Hjv exhibit
overlapping functions for iron signaling to hepcidin. J Mol Med
2015;93:489–98.
[8] Wu Q, Wang H, An P, et al. HJV and HFE play distinct roles in
regulating hepcidin. Antioxid Redox Signal 2015;22:1325–36.
[9] Feder J, Gnirke A, Thomas W, et al. A novel MCH class I-like gene is
mutated in patients with hereditary haemochromatosis. Nature Genet
1996;13:399–408.
[10] Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2
cause iron overload in chromosome 1q-linked juvenile hemochromato-
sis. Nat Genet 2004;36:77–82.
[11] Ehret GB, Munroe PB, Rice KM, et al. Genetic variants in novel
pathways inﬂuence blood pressure and cardiovascular disease risk.
Nature 2011;478:103–9.
[12] Lu X, Wang L, Lin X, et al. Genome-wide association study in Chinese
identiﬁes novel logi for blood pressure and hypertension. Hum Mol
Genet 2015;24:865–74.
[13] Määttä KM, Nikkari ST, Kunnas TA. Genetic variant coding for iron
regulatory protein HFE contributes to hypertension, the TAMRISK
study. Medicine (Baltimore) 2015;94:e464.
[14] Core A, Canali S, Babitt J. Hemojuvelin and bone morphogenetic
protein (BMP) signaling in iron homeostasis. Front Pharmacol 2014;5:
104.
[15] Milet J, Dehais V, Bourgain C, et al. Common variants in the BMP2,
BMP4 and HJV genes of the hepcidin regulation pathway modulate HFE
hemochromatosis penetrance. Am J Hum Genet 2007;81:799–807.
[16] Määttä KM, Nikkari ST, Lähteelä KH, et al. A functional variant in the
serine-threonine kinase coding gene is associated with hypertension: a
case-control study in a Finnish population, the Tampere adult population
cardiovasculat risk study. J Hypertension 2013;31:516–20.
[17] Rodrigues S, Gaunt TR, Day INM. Hardy–Weinberg equilibrium testing
of biological ascertainment for Mendelian randomization studies. Am J
Epidemiol 2009;169:505–14.
[18] Natekar A, Olds RL, Lau MW, et al. Elevated blood pressure: our
family’s fault? The genetics of essential hypertension. Word J Cardiol
2014;6:327–37.
[19] Valenti L,Maloberti A, Signorini S, et al. Iron stores, hepcidin, and aortic
stifness in individuals with hypertension. Plos One 2015;10:e0134635.
[20] Piperno A, Trombini P, Gelosa M, et al. Increased serum ferritin is
common in men with essential hypertension. J Hypertens 2002;20:
1513–8.
[21] Pietrangelo A. Genetics, genetic testing, and management of hemochro-
matosis: 15 years since hepcidin. Gastroenterology 2015;149:1240–51.
[22] Weinberger MH, Fineberg NS, Fineberg SE, et al. Salt sensitivity, pulse
pressure, and death in normal and hypertensive humans. Hypertension
2001;37:429–32.
[23] Marteau J-B, Sass C, Pﬁster M, et al. The Leu554Phe polymorphism in
the E-selectin gene is associated with blood pressure in overweight
people. J Hypertens 2004;22:305–11.
